Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL) -apheresis
- 1 August 1988
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 72 (2-3) , 183-188
- https://doi.org/10.1016/0021-9150(88)90079-2
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Treatment of HypercholesterolemiaAnnual Review of Medicine, 1986
- Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1985
- Effect of plasma exchange with and without concomitant drug treatment on lipids and lipoproteins in patients with familial hypercholesterolemia confirmed by tissue cultureAtherosclerosis, 1985
- Plasma Exchange in the Treatment of Heterozygous Familial HypercholesterolaemiaActa Medica Scandinavica, 1985
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981
- Repetitive intermittent flow plasma exchange in patients with severe hypercholesterolemiaAtherosclerosis, 1981
- Plasma-Exchange Therapy of Homozygous Familial HypercholesterolemiaNew England Journal of Medicine, 1980
- The effects of plasma exchange on cholesterol metabolismAtherosclerosis, 1978
- Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemiaAtherosclerosis, 1978
- PLASMA EXCHANGE IN THE MANAGEMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLÆMIAThe Lancet, 1975